Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

BACKGROUND: The oral proteasome inhibitor ixazomib is under phase 3 clinical investigation in multiple myeloma (MM) in combination with lenalidomide–dexamethasone. This study was conducted to investigate the pharmacokinetic and safety profiles of ixazomib, administered with lenalidomide–dexamethason...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Neeraj, Goh, Yeow Tee, Min, Chang-Ki, Lee, Jae Hoon, Kim, Kihyun, Wong, Raymond S. M., Chim, Chor Sang, Hanley, Michael J., Yang, Huyuan, Venkatakrishnan, Karthik, Hui, Ai-Min, Esseltine, Dixie-Lee, Chng, Wee Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559079/
https://www.ncbi.nlm.nih.gov/pubmed/26337806
http://dx.doi.org/10.1186/s13045-015-0198-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4559079/
https://www.ncbi.nlm.nih.gov/pubmed/26337806
http://dx.doi.org/10.1186/s13045-015-0198-1

Ejemplares similares